Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

Andrew Tutt, Alice Wang, Charles Rowland, Cheryl Gillett, Kit Lau, Karen Chew, Hongyue Dai, Shirley Kwok, Kenneth Ryder, Henry Shu, Robert Springall, Paul Cane, Blair McCallie, Lauren Kam-Morgan, Steve Anderson, Horst Buerger, Joe Gray, James Bennington, Laura Esserman, Trevor HastieSamuel Broder, John Sninsky, Burkhard Brandt, Fred Waldman

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Given the large number of genes purported to be prognostic for breast cancer, it would be optimal if the genes identified are not confounded by the continuously changing systemic therapies. The aim of this study was to discover and validate a breast cancer prognostic expression signature for distant metastasis in untreated, early stage, lymph node-negative (N-) estrogen receptor-positive (ER+) patients with extensive follow-up times. Methods: 197 genes previously associated with metastasis and ER status were profiled from 142 untreated breast cancer subjects. A "metastasis score" (MS) representing fourteen differentially expressed genes was developed and evaluated for its association with distant-metastasis-free survival (DMFS). Categorical risk classification was established from the continuous MS and further evaluated on an independent set of 279 untreated subjects. A third set of 45 subjects was tested to determine the prognostic performance of the MS in tamoxifen-treated women. Results: A 14-gene signature was found to be significantly associated (p <0.05) with distant metastasis in a training set and subsequently in an independent validation set. In the validation set, the hazard ratios (HR) of the high risk compared to low risk groups were 4.02 (95% CI 1.91 - 8.44) for the endpoint of DMFS and 1.97 (95% CI 1.28 to 3.04) for overall survival after adjustment for age, tumor size and grade. The low and high MS risk groups had 10-year estimates (95% CI) of 96% (90 - 99%) and 72% (64-78%) respectively, for DMFS and 91% (84 - 95%) and 68% (61-75%), respectively for overall survival. Performance characteristics of the signature in the two sets were similar. Ki-67 labeling index (LI) was predictive for recurrent disease in the training set, but lost significance after adjustment for the expression signature. In a study of tamoxifen-treated patients, the HR for DMFS in high compared to low risk groups was 3.61 (95% CI 0.86 - 15.14). Conclusion: The 14-gene signature is significantly associated with risk of distant metastasis. The signature has a predominance of proliferation genes which have prognostic significance above that of Ki-67 LI and may aid in prioritizing future mechanistic studies and therapeutic interventions.

Original languageEnglish (US)
Article number339
JournalBMC Cancer
Volume8
DOIs
StatePublished - Nov 21 2008
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Neoplasm Metastasis
Polymerase Chain Reaction
Survival
Genes
Tamoxifen
Lymph Nodes
Odds Ratio

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. / Tutt, Andrew; Wang, Alice; Rowland, Charles; Gillett, Cheryl; Lau, Kit; Chew, Karen; Dai, Hongyue; Kwok, Shirley; Ryder, Kenneth; Shu, Henry; Springall, Robert; Cane, Paul; McCallie, Blair; Kam-Morgan, Lauren; Anderson, Steve; Buerger, Horst; Gray, Joe; Bennington, James; Esserman, Laura; Hastie, Trevor; Broder, Samuel; Sninsky, John; Brandt, Burkhard; Waldman, Fred.

In: BMC Cancer, Vol. 8, 339, 21.11.2008.

Research output: Contribution to journalArticle

Tutt, A, Wang, A, Rowland, C, Gillett, C, Lau, K, Chew, K, Dai, H, Kwok, S, Ryder, K, Shu, H, Springall, R, Cane, P, McCallie, B, Kam-Morgan, L, Anderson, S, Buerger, H, Gray, J, Bennington, J, Esserman, L, Hastie, T, Broder, S, Sninsky, J, Brandt, B & Waldman, F 2008, 'Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature', BMC Cancer, vol. 8, 339. https://doi.org/10.1186/1471-2407-8-339
Tutt, Andrew ; Wang, Alice ; Rowland, Charles ; Gillett, Cheryl ; Lau, Kit ; Chew, Karen ; Dai, Hongyue ; Kwok, Shirley ; Ryder, Kenneth ; Shu, Henry ; Springall, Robert ; Cane, Paul ; McCallie, Blair ; Kam-Morgan, Lauren ; Anderson, Steve ; Buerger, Horst ; Gray, Joe ; Bennington, James ; Esserman, Laura ; Hastie, Trevor ; Broder, Samuel ; Sninsky, John ; Brandt, Burkhard ; Waldman, Fred. / Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. In: BMC Cancer. 2008 ; Vol. 8.
@article{db175c7d4d624128b38f91ad49eb1ff2,
title = "Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature",
abstract = "Background: Given the large number of genes purported to be prognostic for breast cancer, it would be optimal if the genes identified are not confounded by the continuously changing systemic therapies. The aim of this study was to discover and validate a breast cancer prognostic expression signature for distant metastasis in untreated, early stage, lymph node-negative (N-) estrogen receptor-positive (ER+) patients with extensive follow-up times. Methods: 197 genes previously associated with metastasis and ER status were profiled from 142 untreated breast cancer subjects. A {"}metastasis score{"} (MS) representing fourteen differentially expressed genes was developed and evaluated for its association with distant-metastasis-free survival (DMFS). Categorical risk classification was established from the continuous MS and further evaluated on an independent set of 279 untreated subjects. A third set of 45 subjects was tested to determine the prognostic performance of the MS in tamoxifen-treated women. Results: A 14-gene signature was found to be significantly associated (p <0.05) with distant metastasis in a training set and subsequently in an independent validation set. In the validation set, the hazard ratios (HR) of the high risk compared to low risk groups were 4.02 (95{\%} CI 1.91 - 8.44) for the endpoint of DMFS and 1.97 (95{\%} CI 1.28 to 3.04) for overall survival after adjustment for age, tumor size and grade. The low and high MS risk groups had 10-year estimates (95{\%} CI) of 96{\%} (90 - 99{\%}) and 72{\%} (64-78{\%}) respectively, for DMFS and 91{\%} (84 - 95{\%}) and 68{\%} (61-75{\%}), respectively for overall survival. Performance characteristics of the signature in the two sets were similar. Ki-67 labeling index (LI) was predictive for recurrent disease in the training set, but lost significance after adjustment for the expression signature. In a study of tamoxifen-treated patients, the HR for DMFS in high compared to low risk groups was 3.61 (95{\%} CI 0.86 - 15.14). Conclusion: The 14-gene signature is significantly associated with risk of distant metastasis. The signature has a predominance of proliferation genes which have prognostic significance above that of Ki-67 LI and may aid in prioritizing future mechanistic studies and therapeutic interventions.",
author = "Andrew Tutt and Alice Wang and Charles Rowland and Cheryl Gillett and Kit Lau and Karen Chew and Hongyue Dai and Shirley Kwok and Kenneth Ryder and Henry Shu and Robert Springall and Paul Cane and Blair McCallie and Lauren Kam-Morgan and Steve Anderson and Horst Buerger and Joe Gray and James Bennington and Laura Esserman and Trevor Hastie and Samuel Broder and John Sninsky and Burkhard Brandt and Fred Waldman",
year = "2008",
month = "11",
day = "21",
doi = "10.1186/1471-2407-8-339",
language = "English (US)",
volume = "8",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

AU - Tutt, Andrew

AU - Wang, Alice

AU - Rowland, Charles

AU - Gillett, Cheryl

AU - Lau, Kit

AU - Chew, Karen

AU - Dai, Hongyue

AU - Kwok, Shirley

AU - Ryder, Kenneth

AU - Shu, Henry

AU - Springall, Robert

AU - Cane, Paul

AU - McCallie, Blair

AU - Kam-Morgan, Lauren

AU - Anderson, Steve

AU - Buerger, Horst

AU - Gray, Joe

AU - Bennington, James

AU - Esserman, Laura

AU - Hastie, Trevor

AU - Broder, Samuel

AU - Sninsky, John

AU - Brandt, Burkhard

AU - Waldman, Fred

PY - 2008/11/21

Y1 - 2008/11/21

N2 - Background: Given the large number of genes purported to be prognostic for breast cancer, it would be optimal if the genes identified are not confounded by the continuously changing systemic therapies. The aim of this study was to discover and validate a breast cancer prognostic expression signature for distant metastasis in untreated, early stage, lymph node-negative (N-) estrogen receptor-positive (ER+) patients with extensive follow-up times. Methods: 197 genes previously associated with metastasis and ER status were profiled from 142 untreated breast cancer subjects. A "metastasis score" (MS) representing fourteen differentially expressed genes was developed and evaluated for its association with distant-metastasis-free survival (DMFS). Categorical risk classification was established from the continuous MS and further evaluated on an independent set of 279 untreated subjects. A third set of 45 subjects was tested to determine the prognostic performance of the MS in tamoxifen-treated women. Results: A 14-gene signature was found to be significantly associated (p <0.05) with distant metastasis in a training set and subsequently in an independent validation set. In the validation set, the hazard ratios (HR) of the high risk compared to low risk groups were 4.02 (95% CI 1.91 - 8.44) for the endpoint of DMFS and 1.97 (95% CI 1.28 to 3.04) for overall survival after adjustment for age, tumor size and grade. The low and high MS risk groups had 10-year estimates (95% CI) of 96% (90 - 99%) and 72% (64-78%) respectively, for DMFS and 91% (84 - 95%) and 68% (61-75%), respectively for overall survival. Performance characteristics of the signature in the two sets were similar. Ki-67 labeling index (LI) was predictive for recurrent disease in the training set, but lost significance after adjustment for the expression signature. In a study of tamoxifen-treated patients, the HR for DMFS in high compared to low risk groups was 3.61 (95% CI 0.86 - 15.14). Conclusion: The 14-gene signature is significantly associated with risk of distant metastasis. The signature has a predominance of proliferation genes which have prognostic significance above that of Ki-67 LI and may aid in prioritizing future mechanistic studies and therapeutic interventions.

AB - Background: Given the large number of genes purported to be prognostic for breast cancer, it would be optimal if the genes identified are not confounded by the continuously changing systemic therapies. The aim of this study was to discover and validate a breast cancer prognostic expression signature for distant metastasis in untreated, early stage, lymph node-negative (N-) estrogen receptor-positive (ER+) patients with extensive follow-up times. Methods: 197 genes previously associated with metastasis and ER status were profiled from 142 untreated breast cancer subjects. A "metastasis score" (MS) representing fourteen differentially expressed genes was developed and evaluated for its association with distant-metastasis-free survival (DMFS). Categorical risk classification was established from the continuous MS and further evaluated on an independent set of 279 untreated subjects. A third set of 45 subjects was tested to determine the prognostic performance of the MS in tamoxifen-treated women. Results: A 14-gene signature was found to be significantly associated (p <0.05) with distant metastasis in a training set and subsequently in an independent validation set. In the validation set, the hazard ratios (HR) of the high risk compared to low risk groups were 4.02 (95% CI 1.91 - 8.44) for the endpoint of DMFS and 1.97 (95% CI 1.28 to 3.04) for overall survival after adjustment for age, tumor size and grade. The low and high MS risk groups had 10-year estimates (95% CI) of 96% (90 - 99%) and 72% (64-78%) respectively, for DMFS and 91% (84 - 95%) and 68% (61-75%), respectively for overall survival. Performance characteristics of the signature in the two sets were similar. Ki-67 labeling index (LI) was predictive for recurrent disease in the training set, but lost significance after adjustment for the expression signature. In a study of tamoxifen-treated patients, the HR for DMFS in high compared to low risk groups was 3.61 (95% CI 0.86 - 15.14). Conclusion: The 14-gene signature is significantly associated with risk of distant metastasis. The signature has a predominance of proliferation genes which have prognostic significance above that of Ki-67 LI and may aid in prioritizing future mechanistic studies and therapeutic interventions.

UR - http://www.scopus.com/inward/record.url?scp=59349092369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59349092369&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-8-339

DO - 10.1186/1471-2407-8-339

M3 - Article

C2 - 19025599

AN - SCOPUS:59349092369

VL - 8

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 339

ER -